Top of the morning to you, and a fine one, it is. Despite the rising humidity, we are enjoying a shiny sun and hints of a cool breeze wafting about the Pharmalot campus, where the shortest person is now sleeping in, since the local summer job has come to an end. Our own work, however, proceeds apace. And this calls for firing up the coffee kettle and quaffing a few cups of stimulation. Feel free to join us or, if you prefer, grab a mug of water before you tackle your own to-do list. Hope all goes well on your journey today and, as always, do keep in touch …

In a biting letter to Cigna (CI) shareholders, Carl Icahn called the proposed $54 billion acquisition of Express Scripts (ESRX) “completely ridiculous” and argued the insurer is “dramatically overpaying for a highly challenged (company) that is facing existential risks on several fronts.” He cited “regulatory risk” caused by “opposition to the highly flawed rebate system,” which will hurt Express Scripts profits, and pointed to “competitive risk from Amazon (AMZN), arguably the strongest competitor in the world, will be an existential threat to PBMs like Express Scripts, possibly challenging their very existence.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy